Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — Q1 2024 Earnings Presentation
17 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, May 9, 2024
Slide 1: Earnings Presentation 1Q 2024
Earnings Presentation 1Q 2024 Jeddah | 9 May 2024
Slide 2: Business and Strategy Highlights
Business and Strategy Highlights
Slide 3: 1st Quarter 2024 performance highlights
3 Business and Strategy Highlights 1st Quarter 2024 performance highlights Revenue # of Brands Revenue growth accelerated to 28% YoY +2 Consumer Health 1Q 24 +28% YoY driven by a ramp-up in production and new 1Q 24 +11% YoY +1 Ophthalmology product launches +1 Anti-Diabetic SAR mn 385 136 EBITDA EBI
Slide 4: Strategic growth levers for 2024
4 Business and Strategy Highlights Strategic growth levers for 2024 Home Export Portfolio Facilities Business Market Markets Diversification Ramp-up Development Initiatives • Expand in tenders • Consolidate presence • Tap into broader • Accelerate • Enhance business and grow market share segments wi
Slide 5: 1st Quarter Key Highlights and Outlook
5 Business and Strategy Highlights 1st Quarter Key Highlights and Outlook • Overall retail market witnessed unprecedented growth of 19% boosted by sales Saudi Market of diabetes drugs used for weight loss (14% growth ex-diabetes drugs) • JP awarded a 2-year tender (NUPCO) that will reflect consisten
Slide 6: Facilities update
6 Business and Strategy Highlights Facilities update SAR 100bn+ of Total Addressable Market Jeddah Jeddah Egypt Algeria in Core Geographies By 2027 Main Facility Sterile Facility Facility Facility Iraq Kuwait Bahrain Egypt Qatar Kingdom of Saudi Arabia Operational Stability period Operational Operat
Slide 7: Driving revenue growth across key therapeutic areas and geographies
7 Business and Strategy Highlights Driving revenue growth across key therapeutic areas and geographies Revenue Movement by Therapeutic Area, YoY (SARmn) Revenue Movement by Country, YoY (SARmn) +28% +28% 13 14 385 51 9 301 (1) +86% units sold c.40% local mfg. +25% +23% +59% -3% +116% 5 7 5 385 9 9 1
Slide 8: Portfolio diversification through faster expansion into new therapeutic areas
8 Business and Strategy Highlights Portfolio diversification through faster expansion into new therapeutic areas 2021 Revenue Contribution by Therapeutic Area (SARmn) 1Q 2024 Revenue Contribution by Therapeutic Area (SARmn) Pain & Inflammation Anti-diabetic 2% 26% C. Nervous System 5% Ophthalmology
Slide 9: Pipeline overview
9 Business and Strategy Highlights Pipeline overview R&D Status for new Products Under SFDA review Ready for SFDA Submission Under Development Total 12 Ophthalmology 3 15 10 3 General Medicine 1 6 2 Revenue growth EBITDA Dermatology margin 3 3 4 Consumer Health 7 13 2 1 Gastrointestinal 2 8 5 2 Card
Slide 10: Financial Highlights
Lajlé pgana Jamjoom Pharma Financial Highlights “<t—~
Slide 11: 1st Quarter 2024 Key highlights
11 Financial Highlights 1st Quarter 2024 Key highlights Revenue (SARmn) EBITDA (SARmn) +28% +36% 385 137 301 100 EBITDA Margin 33.4% 35.4% 1Q 23 1Q 24 1Q 23 1Q 24 FCF (SARmn) Net Profit (SARmn) +31% +22% 115 103 88 84 FCF conversion 87.5% 84.1% Net Profit Margin 28.1% 26.7% 1Q 23 1Q 24 1Q 23 1Q 24 J
Slide 12: Enhancing operational efficiency...
12 Financial Highlights Enhancing operational efficiency... Cost of Revenue of Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +14% +34% 14 1 119 Cost increase over sales growth reflects 105 increase in Egypt sales as well as ramp-up impact of new facilities (2) 4 136 6 1 R&D/Sales decr
Slide 13: ...to sustain industry-leading margin profile
13 Financial Highlights …to sustain industry-leading margin profile EBITDA Movement YoY (SARmn) EBITDA and Net Profit Margins (%) +36% 33.0% 35.4% 33.4% 31.2% 85 EBITDA Margin 26.0% 35.4% 28.1% 28.8% EBITDA Margin 2 137 33.4% (35) 26.4% 26.7% (14) (1) 21.4% 100 +28% +34% +18% +9% -53% 1Q 23 Revenue
Slide 14: Stabilizing cash conversion cycles amidst strategic business expansion
14 Financial Highlights Stabilizing cash conversion cycles amidst strategic business expansion Cash Conversion Cycle (Days) ▪ Cash conversion cycle increased 7% YoY to 282 days whilst working capital amounted to SAR 634mn, up 12.4%, both increasing at a slower pace than the 28.1% YoY revenue growth
Slide 15: Outlook and Guidance
A Layla pagans Jamjoom Pharma Outlook and Guidance
Slide 16: Re-affirming our guidance
16 Outlook and Guidance Re-affirming our guidance FY 2024-26 Guidance 1Q 2024 Actual Results Revenue growth 12-15% 28.1% EBITDA margin 30.0-31.5% 35.4% CAPEX 4-6% 5.6% Dividend 2H 2023 dividend of SAR 1.5/share 50-60% payout ratio (semi-annual) recommended by the BoD Jamjoom Earnings Presentation -
Slide 17: Q&A Session
Q&A Session Tarek Hosni, Chief Executive Officer Anwer Mohiuddin, Chief Financial Officer Muhammad Bin Khalid, Associate Director – Finance & IR
Jamjoom Pharmaceuticals Factory — Q1 2024 Earnings Presentation on 6ix